{"url_path":"/sec/aibt/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1763329/0001096906-26-000922-index.html","accession_number":"0001096906-26-000922","cik":"0001763329","ticker":"AIBT","issuer_name":"AIBOTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1763329/0001096906-26-000922-index.html","primary_entity_key":"0001763329","primary_entity_name":"AIBOTICS, INC."},"word_count":944,"has_tables":true,"body_markdown":"AIBOTICS, INC. - Form 10-Q SEC filing\n\n0001763329\n--12-31\nAIBOTICS, INC.\nfalse\n2026\nQ1\n\n*iso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\n0001763329\n\n2026-01-01\n2026-03-31\n\n0001763329\n\n2026-03-31\n\n0001763329\n\n2026-06-08\n\n0001763329\n\n2025-12-31\n\n0001763329\nus-gaap:SeriesBPreferredStockMember\n\n2026-03-31\n\n0001763329\nus-gaap:SeriesBPreferredStockMember\n\n2025-12-31\n\n0001763329\nus-gaap:SeriesAPreferredStockMember\n\n2026-03-31\n\n0001763329\nus-gaap:SeriesAPreferredStockMember\n\n2025-12-31\n\n0001763329\n\n2025-01-01\n2025-03-31\n\n0001763329\nus-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nus-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nus-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember\n\n2025-12-31\n\n0001763329\nus-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember\n\n2025-12-31\n\n0001763329\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001763329\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001763329\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001763329\nus-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember\n\n2026-03-31\n\n0001763329\nus-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember\n\n2026-03-31\n\n0001763329\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001763329\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001763329\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001763329\n\n2024-12-31\n\n0001763329\nus-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember\n\n2024-12-31\n\n0001763329\nus-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember\n\n2024-12-31\n\n0001763329\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001763329\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001763329\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001763329\nus-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001763329\nus-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001763329\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001763329\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001763329\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001763329\n\n2025-03-31\n\n0001763329\nus-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember\n\n2025-03-31\n\n0001763329\nus-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember\n\n2025-03-31\n\n0001763329\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001763329\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001763329\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001763329\nus-gaap:EquipmentMember\n\n2026-03-31\n\n0001763329\nus-gaap:IntellectualPropertyMember\n\n2026-03-31\n\n0001763329\nfil:ConvertibleDebt1Member\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:ConvertibleDebt1Member\n\n2025-01-01\n2025-03-31\n\n0001763329\nfil:WarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:WarrantsMember\n\n2025-01-01\n2025-03-31\n\n0001763329\nus-gaap:IntellectualPropertyMember\n\n2025-12-31\n\n0001763329\nfil:MajorShareholderMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:MajorShareholderMember\n\n2025-01-01\n2025-03-31\n\n0001763329\nfil:MajorShareholderMember\n\n2026-03-31\n\n0001763329\nfil:CeoMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:CeoMember\n\n2025-01-01\n2025-03-31\n\n0001763329\nfil:BoardCompensationMember\n\n2026-03-31\n\n0001763329\nfil:BoardCompensationMember\n\n2025-12-31\n\n0001763329\nfil:LenderAMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderGFormerlyLenderAMember\n\n2025-04-22\n2025-04-22\n\n0001763329\nfil:LenderGFormerlyLenderAMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderBMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderCMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderEMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderFMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderGMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderHMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderIMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderGFormerlyLenderAMember\n\n2026-03-31\n\n0001763329\nfil:LenderGFormerlyLenderAMember\n\n2025-12-31\n\n0001763329\nfil:LenderBMember\n\n2026-03-31\n\n0001763329\nfil:LenderBMember\n\n2025-12-31\n\n0001763329\nfil:LenderDMember\n\n2026-01-01\n2026-03-31\n\n0001763329\nfil:LenderDMember\n\n2026-03-31\n\n0001763329\nfil:LenderDMember\n\n2025-12-31\n\n0001763329\nfil:LenderEMember\n\n2026-03-31\n\n0001763329\nfil:LenderEMember\n\n2025-12-31\n\n0001763329\nfil:LenderFMember\n\n2026-03-31\n\n0001763329\nfil:LenderFMember\n\n2025-12-31\n\n0001763329\nfil:LenderGMember\n\n2026-03-31\n\n0001763329\nfil:LenderGMember\n\n2025-12-31\n\n0001763329\nfil:LenderHMember\n\n2026-03-31\n\n0001763329\nfil:LenderHMember\n\n2025-12-31\n\n0001763329\nfil:LenderIMember\n\n2026-03-31\n\n0001763329\nfil:LenderIMember\n\n2025-12-31\n\n0001763329\n\n2024-06-23\n\n0001763329\n\n2024-06-24\n\n0001763329\nfil:StockIssuance8Memberus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001763329\nfil:StockIssuance8Member\n\n2025-01-01\n2025-03-31\n\n0001763329\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-12-31\n\n0001763329\n\n2025-01-01\n2025-12-31\n\n0001763329\nfil:MayConsultingAgreementMember\n\n2025-01-01\n2025-03-31\n\n0001763329\n\n2024-01-01\n2024-12-31\n\n**UNITED STATES SECURITIES AND EXCHANGE COMMISSION** \n\nWashington, D.C. 20549\n\n \n\n**FORM ****10-Q**\n\n \n\n☒\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n \n\n \nFor the quarterly period ended March 31, 2026 \n\n \nOr\n\n☐\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n \n\n \nFor the transition period from _______ to _____\n\n \n \n\nCommission file number: ******000-56022**\n\n \n\n**AIBiotics Therapies, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**\n \n**87-0645794**\n\n(State or other jurisdiction of incorporation or organization)\n \n(I.R.S. Employer Identification No.)\n\n \n \n \n\n**100 SE 2nd Street****,****Suite 2000****, ****Miami****, ****FL********33131**\n\n(Address of principal executive offices, including zip code)\n\n \n\n**954****-****233-3511**\n\n(Registrant’s telephone number, including area code)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n \n\nTitle of each class\nTrading Symbol(s)\nName of each exchange on which registered\n\n**N/A**\n**N/A**\n**N/A**\n\n \n\nSecurities registered pursuant to Section 12(g) of the Act:\n\n \n\n**Common Stock, Par Value $0.001**\n\n(Title of class)\n\n \n\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ** **¨ Yes  x No\n\n \n\nIndicate by check mark if the registrant is not required to file reports pursuant to the Section 13 or Section 15(d) of the Exchange Act. ¨ Yes  x No\n\n \n\n \n \nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes  ¨No\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \nLarge accelerated filer ¨\n \nAccelerated filer ¨\n\n \nNon-accelerated Filer x\n \nSmaller reporting company ☒\n\n \nEmerging growth company ☐\n \n \n\n \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ** **No\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  ☐Yes xNo\n\n \n\nIndicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. As of June 8, 2026, we had 681,985,644 shares of common stock outstanding.\n \n\n**AIBiotics Therapies, Inc.**\n**Form 10-Q for the Quarter Ended March 31, 2026** \n \n**TABLE OF CONTENTS**\n \nItem\n \nPage\n\n \n**Part I—Financial Information**\n \n\n \n \n \n\n1\nFinancial Statements\n4\n\n \nCondensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 2025\n4\n\n \nCondensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (unaudited)\n5\n\n \nCondensed Consolidated Statements of Mezzanine Equity and Stockholders’ Deficit for the Three Months Ended March 31, 2026 and 2025 (unaudited)\n6\n\n \nCondensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (unaudited)\n7\n\n \nNotes to the Unaudited Condensed Consolidated Financial Statements\n8\n\n2\nManagement’s Discussion and Analysis of Financial Condition and Results of Operations\n17\n\n3\nQuantitative and Qualitative Disclosures about Market Risk\n19\n\n4\nControls and Procedures\n20\n\n \n \n \n\n \n**Part II—Other Information**\n \n\n \n \n \n\n6\nExhibits\n20\n\n \nSignatures\n21\n\n**PART I–FINANCIAL INFORMATION**"}